Ankylosing Spondylitis Patients Commencing Biologic Therapy Have High Baseline Levels of Comorbidity: A Report from the Australian Rheumatology Association Database
International Journal of Rheumatology · 2009
DOI: 10.1155/2009/268569 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Rheumatology, 2009. Verfasst von John Oldroyd und 8 weiteren Autor:innen. Beteiligte Einrichtung: Monash Department of Clinical Epidemiology, Cabrini Institute, 183 Wattletree Road, Malvern, VIC 3144, Australia. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 3.0). Gefördert von: National Health and Medical Research Council, Monash University, Wyeth.
Abstract (Originalsprache)
Aims
To compare the baseline characteristics of a population-based cohort of patients with ankylosing spondylitis (AS) commencing biological therapy to the reported characteristics of bDMARD randomised controlled trials (RCTs) participants.
Methods
Descriptive analysis of AS participants in the Australian Rheumatology Association Database (ARAD) who were commencing bDMARD therapy.
Results
Up to December 2008, 389 patients with AS were enrolled in ARAD. 354 (91.0%) had taken bDMARDs at some time, and 198 (55.9%) completed their entry questionnaire prior to or within 6 months of commencing bDMARDs. 131 (66.1%) had at least one comorbid condition, and 24 (6.8%) had a previous malignancy (15 nonmelanoma skin, 4 melanoma, 2 prostate, 1 breast, cervix, and bowel). Compared with RCT participants, ARAD participants were older, had longer disease duration and higher baseline disease activity.
Conclusions
AS patients commencing bDMARDs in routine care are significantly different to RCT participants and have significant baseline comorbidities.
Autor:innen und Institutionen
- Monash Department of Clinical Epidemiology, Cabrini Institute, 183 Wattletree Road, Malvern, VIC 3144, Australia.
Förderung
- National Health and Medical Research Council
- Monash University
- Wyeth
- Sanofi-Aventis Australia
Zitieren
APA
Oldroyd, J., Schachna, L., Buchbinder, R., Staples, M., Murphy, B., Bond, M., Briggs, A., Lassere, M., & March, L. (2009). Ankylosing Spondylitis Patients Commencing Biologic Therapy Have High Baseline Levels of Comorbidity: A Report from the Australian Rheumatology Association Database. International Journal of Rheumatology. https://doi.org/10.1155/2009/268569
Vancouver
Oldroyd J, Schachna L, Buchbinder R, Staples M, Murphy B, Bond M, et al. Ankylosing Spondylitis Patients Commencing Biologic Therapy Have High Baseline Levels of Comorbidity: A Report from the Australian Rheumatology Association Database. International Journal of Rheumatology. 2009. doi:10.1155/2009/268569
BibTeX
@article{Oldroyd2009,
author = {Oldroyd, John and Schachna, Lionel and Buchbinder, Rachelle and Staples, Margaret and Murphy, Bridie and Bond, Molly and Briggs, Andrew and Lassere, Marissa and March, Lyn},
title = {Ankylosing Spondylitis Patients Commencing Biologic Therapy Have High Baseline Levels of Comorbidity: A Report from the Australian Rheumatology Association Database},
journal = {International Journal of Rheumatology},
year = {2009},
doi = {10.1155/2009/268569}
}
EUVIMED